Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti‐angiogenic treatment has limited efficacy due to therapy‐induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy‐induced resistance. We show that Apelin inhibition potently remodels the tumor microenvironment, reducing angiogenesis, and effectively blunting tumor growth. Functionally, targeting Apelin improves vessel function and reduces polymorphonuclear myeloid‐derived suppressor cell infiltration. Importantly, in mammary and lung cancer, Apelin prevents resistance to anti‐angiogenic receptor tyrosine kinase (RTK) inhibitor therapy, reducing growth and angiogenesis in lung and breast cancer models without increased hypoxia in the tumor microenvironment. Apelin blockage also prevents RTK inhibitor‐induced metastases, and high Apelin levels correlate with poor prognosis of anti‐angiogenic therapy patients. These data identify a druggable anti‐angiogenic drug target that reduces tumor blood vessel densities and normalizes the tumor vasculature to decrease metastases. Apelin is an angiogenic peptide implicated in embryonic and tumor angiogenesis. This study highlights Apelin targeting as a cancer therapy alone or in combination with current anti‐angiogenic therapies to reduce tumour growth and improve vessel structure and functionality, and thus survival. Apelin is an angiogenic peptide implicated in embryonic and tumor angiogenesis. This study highlights Apelin targeting as a cancer therapy alone or in combination with current anti‐angiogenic therapies to reduce tumour growth and improve vessel structure and functionality, and thus survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Preventing cancer hypoxia may therefore provide a mechanistic rationale for combination therapy with chemotherapeutics and radiation therapy, other anti-angiogenic treatments, perhaps even immune therapy (Mauceri et al, 1998; Jain, 2005).”
BackgroundMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 4×
“…EMBO Molecular Medicine 11: e9266 | 2019 1 of 19 The large-scale eradication of tumor blood vessels results in necrosis and hypoxia, which can trigger several resistance mechanisms that drive tumor regrowth and malignancy (Bergers & Hanahan, 2008; Carmeliet & Jain, 2011a; Potente et al, 2011).”
BackgroundInfluentialGyörffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169 · cited 3×
“Apelin blockage improves survival in mammary and lung cancer models To corroborate that Apelin expression is associated with outcome in human breast cancer, we performed an unbiased meta-analysis of multiple datasets using the Kmplot (Györffy et al, 2010) and PrognoScan (Mizuno et al, 2009) databases.”
MethodFull-length RNA-seq from single cells using Smart-seq2
Picelli, S., Faridani, O. R., Björklund, Å. K., Winberg, G., Sagasser, S., & Sandberg, R. (2014) · Nature Protocols · doi:10.1038/nprot.2014.006 · Cited by 4,137 · cited 1×
“Full RNA was isolated from sorted tumor endothelial cells (TEC) and prepared as described by Picelli et al (2014), with the following changes: Cells were sorted in 4 ll lysis buffer, to which oligo-dT and dNTP were added.”
MethodModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 3×
“…EMBO Molecular Medicine 11: e9266 | 2019 1 of 19 The large-scale eradication of tumor blood vessels results in necrosis and hypoxia, which can trigger several resistance mechanisms that drive tumor regrowth and malignancy (Bergers & Hanahan, 2008; Carmeliet & Jain, 2011a; Potente et al, 2011).”
BackgroundBasic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“However, this strategy increased hypoxia (Koh et al, 2010; Rigamonti et al, 2014; Scholz et al, 2016), which can worsen the tumor microenvironment and induce treatment resistance (Jain, 2014).”
BackgroundCombined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646 · cited 1×
“Angiogenic proteins, like VEGF, have been reported to be able to affect immune cell infiltration in different tumor models (Yang et al, 2018).”
BackgroundSchmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., Laoui, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9670 · Cited by 582 · cited 1×
“…growth, angiogenesis, vascular abnormality, and metastasis (Brown et al, 2010; Koh et al, 2010; Kienast et al, 2013; Rigamonti et al, 2014; Scholz et al, 2016; Allen et al, 2017; Schmittnaegel et al, 2017), thus increasing the promise of anti-angiogenic VEGF-targeting in combinatory therapies.”
BackgroundIdentification and functional analysis of endothelial tip cell–enriched genes
del Toro, R., Prahst, C., Mathivet, T., Siegfried, G., Kaminker, J. S., Larrivee, B., Breant, C., Duarte, A., Takakura, N., Fukamizu, A., et al. (2010) · Blood · doi:10.1182/blood-2010-02-270819 · Cited by 474
Self-citationExtracellular Metabolic Energetics Can Promote Cancer Progression
Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., Saltz, L., Paty, P. B., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2014.12.018 · Cited by 393
Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D.-C., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.018 · Cited by 327
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
Hypoxia Signaling in Cancer: From Basics to Clinical Practice
Sebestyén, A., Kopper, L., Dankó, T., & Tímár, J. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.1609802 · Cited by 110
Platelets in aging and cancer—“double-edged sword”
Faria, A. V. S., Andrade, S. S., Peppelenbosch, M. P., Ferreira-Halder, C. V., & Fuhler, G. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09926-2 · Cited by 38
Famta, P., Shah, S., Vambhurkar, G., Pandey, G., Bagasariya, D., Kumar, K. C., Prasad, S. B., Shinde, A., Wagh, S., Srinivasarao, D. A., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01669-9 · Cited by 21
Metadata
- Authors
- Uribesalgo, I., Hoffmann, D., Zhang, Y., Kavirayani, A., Lazovic, J., Berta, J., Novatchkova, M., Pai, T., Wimmer, R. A., László, V., Schramek, D., Karim, R., Tortola, L., Deswal, S., Haas, L., Zuber, J., Szűcs, M., Kuba, K., Dome, B., Cao, Y., Haubner, B. J., & Penninger, J. M.
- Venue
- EMBO Molecular Medicine
- Published
- 2019-06-24
- Volume
- 11
- Issue
- 8
- Pages
- e9266-e9266
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2952975115
- Cited by
- 114
- References
- 16
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.